Tags

Type your tag names separated by a space and hit enter

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.
Hum Gene Ther. 2014 Apr; 25(4):285-300.HG

Abstract

Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further addressed. Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera, suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in humans. In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective gene therapy vehicles.

Authors+Show Affiliations

1 Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA, United Kingdom .No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24499174

Citation

Lopez-Gordo, Estrella, et al. "Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors." Human Gene Therapy, vol. 25, no. 4, 2014, pp. 285-300.
Lopez-Gordo E, Podgorski II, Downes N, et al. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther. 2014;25(4):285-300.
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014). Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Human Gene Therapy, 25(4), 285-300. https://doi.org/10.1089/hum.2013.228
Lopez-Gordo E, et al. Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors. Hum Gene Ther. 2014;25(4):285-300. PubMed PMID: 24499174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. AU - Lopez-Gordo,Estrella, AU - Podgorski,Iva I, AU - Downes,Nicholas, AU - Alemany,Ramon, Y1 - 2014/03/25/ PY - 2014/2/7/entrez PY - 2014/2/7/pubmed PY - 2014/12/15/medline SP - 285 EP - 300 JF - Human gene therapy JO - Hum Gene Ther VL - 25 IS - 4 N2 - Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further addressed. Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera, suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in humans. In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective gene therapy vehicles. SN - 1557-7422 UR - https://www.unboundmedicine.com/medline/citation/24499174/Circumventing_antivector_immunity:_potential_use_of_nonhuman_adenoviral_vectors_ L2 - https://www.liebertpub.com/doi/10.1089/hum.2013.228?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -